Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Core Insights - Propanc Biopharma's lead asset, PRP, is positioned as a novel therapeutic approach for treating and preventing metastatic cancer, particularly in aggressive solid tumors like pancreatic cancer, which has a low five-year survival rate of 13% compared to an overall cancer survival rate of 70% [1][2]. Company Overview - Propanc Biopharma, Inc. is focused on developing innovative treatments for chronic diseases, including cancer, by targeting cancer stem cells to prevent recurrence and metastasis [7]. Product Details - PRP is an investigational proenzyme therapy composed of trypsinogen and chymotrypsinogen in a 1:6 ratio, delivered intravenously. It aims to selectively target cancer stem cells, inhibit metastasis, disrupt the tumor microenvironment, reduce angiogenesis, and enhance the effectiveness of standard treatments with lower toxicity [3][6]. Market Potential - The global pancreatic cancer treatment market is valued at approximately $4.42 billion in 2026 and is projected to grow to $14.43 billion by 2034, reflecting a compound annual growth rate (CAGR) of around 16% due to increasing cases and demand for improved treatment options [5]. Clinical Development - Propanc is preparing for a Phase 1b First-In-Human trial in 2026, which will involve 30-40 patients with advanced solid tumors. The company has secured $100 million in funding, obtained new patents, and received FDA Orphan Drug status for pancreatic cancer [5]. Preclinical Data - Preclinical studies have shown that PRP can achieve over 85% tumor growth inhibition in pancreatic cancer models, reduce fibrosis and resistance markers, and has a favorable safety profile with no major side effects reported in limited prior human use [4].